摘要
目的探讨细胞分裂相关基因mRNA(NUF2 mRNA)以及铁调素mRNA(HAMP mRNA)在肾透明细胞癌(KIRC)预后判断中的运用。方法从TCGA数据库下载KIRC患者基因表达数据,分析NUF2 mRNA、Hepcidin mRNA与对照组的表达差异及表达水平与患者的总生存率的关系。采用多因素COX分析获得患者总生存(OS)的预后因素,根据独立预后因素构建患者的预后评估模型,并对该模型对患者的预后的评价效果进行分析。结果KIRC患者的NUF2 mRNA及HAMP mRNA高于对照组,高表达患者的预后差于低表达患者;多因素COX回归分析表明NUF2 mRNA、HAMP mRNA、分期、病理分级及年龄是患者的独立预后危险因素;基于NUF2 mRNA、HAMP mRNA、分期、病理分级及年龄的预后评估模型评估的高风险组患者的OS低于低风险组,1、2、3年OS分别为81.4%、70.7%及60.5%;预后评估模型1、2、3年的ROC曲线下面积分别为0.816、0.800及0.793。结论基于NUF2 mRNA、HAMP mRNA、分期、病理分级及年龄构建的预后评估模型能更准确的判断KIRC患者的预后。
Objective To investigate the application of NUF2 mRNA and HAMP mRNA in the prognosis of kidney renal clear cell carcinoma(KIRC).Methods The gene expression data of KIRC patients were downloaded from the TCGA database,and the expression differences of NUF2 mRNA,Hepcidin mRNA and the control group and the relationship between the expression level and the overall survival rate of the patients were analyzed.Multivariate COX analysis was used to obtain the prognostic factors of overall survival(OS).The prognostic evaluation model of patients was constructed according to independent prognostic factors,and the evaluation effect of the model on the prognosis of patients was analyzed.Results The NUF2 mRNA and HAMP mRNA of KIRC patients were higher than those of the control group,and the prognosis of patients with high expression was worse than that of patients with low expression.Multivariate COX regression analysis showed that NUF2 mRNA,HAMP mRNA,stage,pathological grade and age were independent prognostic risk factors for patients.The OS of patients in the high-risk group evaluated by the prognostic evaluation model based on NUF2 mRNA,HAMP mRNA,stage,pathological grade and age was lower than that in the low-risk group,and the 1-year,2-year and 3-year OS were 81.4%,70.7%and 60.5%,respectively.The area under the ROC curve of the prognostic evaluation model 1,2 and 3 years was 0.816,0.800 and 0.793,respectively.Conclusion The prognostic evaluation model based on NUF2 mRNA,HAMP mRNA,stage,pathological grade and age can more accurately judge the prognosis of KIRC patients.
作者
单丽
朱晓力
向程程
张媛
顾国建
程旭
SHAN Li;ZHU Xiao-li;XIANG Cheng-cheng;ZHANG Yuan;GU Guo-jian;CHENG Xu(Department of Oncology,Taicang Hospital of Suzhou University/the First People's Hospital of Taicang,Taicang 215400,Jiangsu,China;Department of Pathology,Taicang Hospital of Suzhou University/the First People's Hospital of Taicang,Taicang 215400,Jiangsu,China)
出处
《医学信息》
2023年第9期42-47,共6页
Journal of Medical Information
基金
苏州市科技局2021年度苏州市科技发展计划(编号:SKJYD2021015)。